Wellbutrin XL (Bupropion HCl) Patent Expiration, LOE Window & CMS Spending

Wellbutrin XL (Bupropion HCl) by Bausch Health: Off-Patent Genericized (AB Competition), 32 AB generics, $106.0M 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN021515 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors32
2024 CMS Total Public Spend$106.0M
2024 Medicare Part D Spend$81.9M
2024 Medicaid Spend$24.1M
Reported Wholesale Price Change (CA SB 17)15 WAC filings (max 45.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.